X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FDC LTD. NATCO PHARMA/
FDC LTD.
 
P/E (TTM) x 13.9 17.8 78.1% View Chart
P/BV x 4.0 4.0 99.4% View Chart
Dividend Yield % 1.1 1.2 94.8%  

Financials

 NATCO PHARMA   FDC LTD.
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
FDC LTD.
Mar-14
NATCO PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,080144 752.6%   
Low Rs67179 849.7%   
Sales per share (Unadj.) Rs592.147.6 1,244.8%  
Earnings per share (Unadj.) Rs188.47.6 2,476.0%  
Cash flow per share (Unadj.) Rs206.39.0 2,290.1%  
Dividends per share (Unadj.) Rs8.252.25 366.7%  
Dividend yield (eoy) %0.92.0 46.6%  
Book value per share (Unadj.) Rs833.647.5 1,753.7%  
Shares outstanding (eoy) m36.90177.83 20.8%   
Bonus/Rights/Conversions ISBB-  
Price / Sales ratio x1.52.3 63.2%   
Avg P/E ratio x4.614.6 31.8%  
P/CF ratio (eoy) x4.212.3 34.4%  
Price / Book Value ratio x1.12.3 44.9%  
Dividend payout %4.429.6 14.8%   
Avg Mkt Cap Rs m32,31119,784 163.3%   
No. of employees `0004.8NA-   
Total wages/salary Rs m3,2561,221 266.8%   
Avg. sales/employee Rs Th4,522.5NM-  
Avg. wages/employee Rs Th674.0NM-  
Avg. net profit/employee Rs Th1,439.0NM-  
INCOME DATA
Net Sales Rs m21,8488,459 258.3%  
Other income Rs m404394 102.7%   
Total revenues Rs m22,2528,852 251.4%   
Gross profit Rs m9,2842,070 448.5%  
Depreciation Rs m662249 265.8%   
Interest Rs m15431 496.6%   
Profit before tax Rs m8,8722,184 406.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920606 317.1%   
Profit after tax Rs m6,9521,353 513.8%  
Gross profit margin %42.524.5 173.6%  
Effective tax rate %21.627.7 78.0%   
Net profit margin %31.816.0 198.9%  
BALANCE SHEET DATA
Current assets Rs m21,3074,355 489.2%   
Current liabilities Rs m5,9201,792 330.4%   
Net working cap to sales %70.430.3 232.4%  
Current ratio x3.62.4 148.1%  
Inventory Days Days7344 164.8%  
Debtors Days Days10725 431.8%  
Net fixed assets Rs m14,9863,025 495.4%   
Share capital Rs m369179 206.6%   
"Free" reserves Rs m30,3538,243 368.2%   
Net worth Rs m30,7608,453 363.9%   
Long term debt Rs m011 0.0%   
Total assets Rs m37,15110,557 351.9%  
Interest coverage x58.671.4 82.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 73.4%   
Return on assets %19.113.1 145.9%  
Return on equity %22.616.0 141.2%  
Return on capital %29.323.5 124.8%  
Exports to sales %013.3 0.0%   
Imports to sales %03.3 0.0%   
Exports (fob) Rs mNA1,126 0.0%   
Imports (cif) Rs mNA283 0.0%   
Fx inflow Rs m10,3221,146 900.6%   
Fx outflow Rs m2,978355 838.3%   
Net fx Rs m7,343791 928.6%   
CASH FLOW
From Operations Rs m4,6361,485 312.2%  
From Investments Rs m-11,155-620 1,800.6%  
From Financial Activity Rs m6,509-753 -865.0%  
Net Cashflow Rs m-18113 -16.0%  

Share Holding

Indian Promoters % 52.0 68.9 75.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.7 166.8%  
FIIs % 16.6 7.5 221.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 19.0 136.8%  
Shareholders   25,395 23,730 107.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  UNICHEM LAB  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ABBOTT INDIA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS